Elevated CD55 and CD59 levels are linked to reduced survival in multiple cancers, including BLCA, aligning with our findings that key complement-related proteins drive BLCA progression through their interaction with the TME [30]. This evidence concerns the gene CD59 and bladder transitional cell carcinoma.